Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

• DOI: 10.1158/1078-0432.ccr-10-0026
• Publication Date: 2010-05-12T02:04:43Z
• Authors: Jennifer M. Specht; Brenda F. Kurland; Susan K. Montgomery; Lisa K. Dunnwald; Robert K. Doot; Julie R. Gralow; Georgina K. Ellis; Hannah M. Linden; Robert B. Livingston; Kimberly H. Allison; Erin K. Schubert; David A. Mankoff
• Keywords: Progesterone receptor

Abstract Purpose: Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive response. This analysis examines tumor by subtype. Experimental Design: Tumor subtype was defined immunohistochemistry 71 with locally advanced undergoing NC. Subtype as luminal [estrogen receptor (ER)/progesterone (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor 2 (HER2) negative], HER2 (ER/PR overexpressing). Metabolic rate (MRFDG) blood flow (BF) were calculated from PET before Pathologic complete response (pCR) to NC classified pCR versus other. Results: Twenty-five (35%) had TN tumors; 6 (8%) 40 (56%) luminal. MRFDG for tumors on average 67% greater than (95% confidence interval, 9-156%) MRFDG/BF ratio 53% compared 9-114%; P < 0.05 both). Average BF levels did not differ (P = 0.73). Most showed relatively low (and achieve pCR); high generally matched predicted pCR. true tumors. Conclusion: The relationship between differed predicts poor more common Metabolism measures may subsets susceptible resistant help direct targeted therapy. Clin Cancer Res; 16(10); 2803–10. ©2010 AACR.